High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV)
| Autor: | D. Bacca, V. Tagarielli, Valeria Piazzolla, Immacolata Carraturo, F. Sogari, Nicola Minerva, A. Gesualdo, A. Giannelli, Rosanna Santoro, Ruggero Losappio, Gianfranco Lauletta, Domenico Potenza, M. Mazzola, E. Visaggi, Alessandra Mangia |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Cirrhosis Hepatology business.industry Ribavirin medicine.disease Sofosbuvir/velpatasvir Gastroenterology 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology chemistry Internal medicine medicine In real life In patient business |
| Zdroj: | Journal of Hepatology. 68:S273-S274 |
| ISSN: | 0168-8278 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect